Neville Rodie & Shaw’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$42.7M Sell
168,188
-1,745
-1% -$407K 2.76% 7
2026
Q1
$41.5M Buy
169,933
+3,748
+2% +$873K 3.02% 6
2025
Q4
$34.4M Buy
166,185
+3,503
+2% +$693K 2.43% 10
2025
Q3
$30.2M Sell
162,682
-6,555
-4% -$1.12M 2.18% 10
2025
Q2
$25.9M Sell
169,237
-2,855
-2% -$439K 1.92% 14
2025
Q1
$28.5M Sell
172,092
-7,297
-4% -$1.14M 2.23% 10
2024
Q4
$25.9M Sell
179,389
-1,379
-0.8% -$214K 1.89% 13
2024
Q3
$29.3M Sell
180,768
-8,208
-4% -$1.31M 2.16% 8
2024
Q2
$27.6M Sell
188,976
-31,127
-14% -$4.63M 2.1% 12
2024
Q1
$34.8M Sell
220,103
-5,239
-2% -$834K 2.66% 8
2023
Q4
$35.3M Sell
225,342
-3,749
-2% -$575K 2.89% 6
2023
Q3
$35.7M Sell
229,091
-1,186
-0.5% -$196K 3.18% 5
2023
Q2
$38.1M Sell
230,277
-3,155
-1% -$509K 3.28% 4
2023
Q1
$36.2M Sell
233,432
-2,794
-1% -$451K 3.28% 4
2022
Q4
$41.7M Buy
236,226
+90
+0% +$15.5K 3.92% 3
2022
Q3
$38.6M Sell
236,136
-3,567
-1% -$604K 3.79% 4
2022
Q2
$42.5M Sell
239,703
-2,321
-1% -$414K 3.81% 4
2022
Q1
$43.1M Sell
242,024
-835
-0.3% -$142K 3.21% 5
2021
Q4
$41.5M Sell
242,859
-2,849
-1% -$466K 2.94% 5
2021
Q3
$39.7M Sell
245,708
-2,869
-1% -$489K 3.08% 6
2021
Q2
$41M Sell
248,577
-166
-0.1% -$27.5K 3.15% 6
2021
Q1
$40.9M Sell
248,743
-1,888
-0.8% -$305K 3.39% 5
2020
Q4
$39.4M Sell
250,631
-5,079
-2% -$750K 3.42% 5
2020
Q3
$38.1M Buy
255,710
+590
+0.2% +$87.3K 3.59% 5
2020
Q2
$35.9M Sell
255,120
-2,636
-1% -$384K 3.71% 5
2020
Q1
$33.8M Sell
257,756
-1,370
-0.5% -$194K 4.12% 2
2019
Q4
$37.8M Buy
259,126
+3,483
+1% +$472K 3.71% 2
2019
Q3
$33.1M Buy
255,643
+6,307
+3% +$831K 3.5% 3
2019
Q2
$34.7M Sell
249,336
-7,133
-3% -$987K 3.68% 3
2019
Q1
$35.9M Sell
256,469
-2,445
-0.9% -$328K 3.8% 3
2018
Q4
$33.4M Buy
258,914
+2,100
+0.8% +$293K 4.05% 3
2018
Q3
$35.5M Sell
256,814
-2,698
-1% -$359K 3.5% 3
2018
Q2
$31.5M Sell
259,512
-4,785
-2% -$597K 3.32% 3
2018
Q1
$33.9M Buy
264,297
+1,575
+0.6% +$213K 3.73% 3
2017
Q4
$36.7M Buy
262,722
+505
+0.2% +$70.3K 3.87% 3
2017
Q3
$34.1M Sell
262,217
-2,295
-0.9% -$304K 3.8% 3
2017
Q2
$35M Sell
264,512
-12,031
-4% -$1.53M 3.99% 3
2017
Q1
$34.4M Sell
276,543
-5,609
-2% -$670K 3.94% 3
2016
Q4
$32.5M Sell
282,152
-5,256
-2% -$607K 3.83% 3
2016
Q3
$34M Sell
287,408
-1,790
-0.6% -$217K 4% 3
2016
Q2
$35.1M Sell
289,198
-805
-0.3% -$91.5K 4.2% 2
2016
Q1
$31.4M Sell
290,003
-1,231
-0.4% -$127K 3.81% 3
2015
Q4
$29.9M Sell
291,234
-9,572
-3% -$963K 3.6% 3
2015
Q3
$28.1M Sell
300,806
-8,193
-3% -$793K 3.44% 3
2015
Q2
$30.1M Sell
308,999
-12,248
-4% -$1.23M 3.3% 3
2015
Q1
$32.3M Sell
321,247
-10,301
-3% -$1.05M 3.36% 3
2014
Q4
$34.7M Sell
331,548
-2,506
-0.8% -$264K 3.51% 3
2014
Q3
$35.6M Buy
334,054
+13,355
+4% +$1.39M 3.51% 3
2014
Q2
$33.6M Buy
320,699
+15,650
+5% +$1.58M 3.37% 3
2014
Q1
$30M Sell
305,049
-5,057
-2% -$469K 3.24% 3
2013
Q4
$28.4M Sell
310,106
-7,314
-2% -$674K 3.07% 3
2013
Q3
$27.5M Sell
317,420
-968
-0.3% -$86.8K 3.21% 3
2013
Q2
$27.3M Buy
+318,388
New +$27M 3.31% 3

Other funds holding JNJ

Neville Rodie & Shaw's JNJ Position: Q2 2026 in Review

Neville Rodie & Shaw reduced its Johnson & Johnson (JNJ) stake by 1% in Q2 2026, selling an estimated $407K and leaving 168,188 shares worth $42.7M. The position accounts for 2.76% of the portfolio, ranked #7.

Neville Rodie & Shaw first reported a position in JNJ in Q2 2013 and has held it in 53 quarters since. The position peaked at $43.1M in Q1 2022. 1,411 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Neville Rodie & Shaw held 168,188 shares of Johnson & Johnson worth $42.7M as of Q2 2026.
  • Neville Rodie & Shaw sold 1,745 Johnson & Johnson shares in Q2 2026, an estimated $407K.
  • Johnson & Johnson made up 2.76% of Neville Rodie & Shaw's portfolio in Q2 2026, its #7 holding.
  • Neville Rodie & Shaw first reported a position in Johnson & Johnson in Q2 2013 and has held it in 53 quarters since.
  • Neville Rodie & Shaw's Johnson & Johnson position peaked at $43.1M in Q1 2022.
  • 1,411 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Neville Rodie & Shaw's 13F filing for Q2 2026, filed 6 Jul 2026.